Free Float 83,13 %
Shares Float 16,46 M
Shares Outstanding 19,8 M
GRANITESHARES BLOOMBERG COMMODITY BROAD STRATEGY NO K-1 ETF
Share · SE0016101935 (ARCX)
No Price
n/a
Share Float & Liquidity
Asset Allocation
| Asset | Percentage % |
|---|---|
| Cash | 76,09 % |
| Other | 16,95 % |
| Bond | 6,96 % |
| NotClassified | 0,00 % |
| Stock non-US | 0,00 % |
| Stock US | 0,00 % |
Largest Positions
| Symbol | ISIN | Name | Percentage % |
|---|---|---|---|
| US Dollars | 15,60 % | ||
| US TBill 07/29/.. | 7,76 % | ||
| US TBill 07/27/.. | 7,76 % | ||
| US TBill 08/26/.. | 6,84 % | ||
| US TBill 07/13/.. | 6,84 % | ||
| US TBill 08/12/.. | 6,84 % | ||
| US TBill 07/08/.. | 6,39 % | ||
| US TBill 07/22/.. | 5,93 % | ||
| US TBill 06/17/.. | 5,47 % | ||
| US TBill 08/19/.. | 5,02 % |
Region Distribution
| Region | Percentage % |
|---|---|
| Africa/Middle East | 0,00 % |
| Asia Developed | 0,00 % |
| Asia Emerging | 0,00 % |
| Australasia | 0,00 % |
| Europe Developed | 0,00 % |
| Europe Emerging | 0,00 % |
| Japan | 0,00 % |
| Latin America | 0,00 % |
| North America | 0,00 % |
| United Kingdom | 0,00 % |
Sector Distribution
| Sector | Percentage % |
|---|---|
| Grundstoffe | 0,00 % |
| Verbrauchsgüter | 0,00 % |
| Finanzdienstleistungen | 0,00 % |
| Immobilien | 0,00 % |
| Telekommunikation | 0,00 % |
| Energie | 0,00 % |
| Industrieunternehmen | 0,00 % |
| Technologie | 0,00 % |
| Basiskonsumgüter | 0,00 % |
| Gesundheitswesen | 0,00 % |
Company Profile for GRANITESHARES BLOOMBERG COMMODITY BROAD STRATEGY NO K-1 ETF Share
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
Fund Master Data
Issuer Graniteshares
Asset Class ETF
Name GraniteShares Bloomberg Commodity Broad Strategy No K-1 ETF
Fund Currency USD
Category Commodities Broad Basket
Morningstar Rating 3
Fund Key Figures
Fund Size 221.823,31 EUR
Investment Strategy
The investment seeks to provide long-term capital appreciation, primarily through exposure to commodity futures markets. The fund is an actively managed ETF that seeks to provide long-term capital appreciation, primarily through exposure to commodity futures markets. While the fund generally will seek exposure to the commodity futures markets included in the COMB Benchmark, it is not an index tracking ETF and will seek to improve its performance, in part through a cash management strategy consisting of investments in investment grade fixed income securities. The fund is non-diversified.
Company Data
Name GRANITESHARES BLOOMBERG COMMODITY BROAD STRATEGY NO K-1 ETF
Company CombiGene AB (publ)
Website
https://www.combigene.com
Primary Exchange 
NYSE
NYSE
ISIN SE0016101935
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Peter Ekolind
Market Capitalization 49 Mio
Country Sweden
Currency USD
Employees 0,0 T
Address Agavagen 52A, 181 55 Lidingö
IPO Date 2015-05-25
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ STOCKHOLM AB | COMBI.ST |
| Frankfurt | COJ0.F |
More Shares
Investors who hold GRANITESHARES BLOOMBERG COMMODITY BROAD STRATEGY NO K-1 ETF also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
